USPTO serial 88807844
RED CELL THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 19, 2021
- Examiner
- FALK, JONATHAN ROBERT
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with RED CELL THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210-2206UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations of engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; engineered erythroid cells for medical or clinical use for the treatment of a variety of human diseases and conditions, namely, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, metabolic diseases and disorders, genetic diseases and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, hematological diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; none of the foregoing used as vitamin-mineral supplements or for animals | ACTIVE | Nov 11, 2020 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 19, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 19, 2021 | R.SR | REGISTERED-SUPPLEMENTAL REGISTER | Your mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application. |
| Sep 15, 2021 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 7, 2021 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| Sep 7, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 7, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 7, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 7, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 21, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 20, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 20, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2021 | AAUA | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | — |
| Feb 6, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2021 | IUAA | USE AMENDMENT ACCEPTED | — |
| Jan 12, 2021 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Nov 20, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 19, 2020 | IUAF | USE AMENDMENT FILED | — |
| Nov 19, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 19, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 19, 2020 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| May 20, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2020 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Mar 13, 2020 | ALIE | ASSIGNED TO LIE | — |
| Mar 6, 2020 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 27, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 27, 2020 | NWAP | NEW APPLICATION ENTERED | — |